United States - English - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate usp is indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds. safety and effectiveness in children below the age of 10 have not been established. accidental ingestion resulting in death has been reported in children below age 10. keep out of reach of children.

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals llc - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37) - omeprazole 40 mg - omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: - short-term treatment of active duodenal ulcer (1.1) - short-term treatment of active benign gastric ulcer (1.2) - treatment of gastroesophageal reflux disease (gerd) (1.3) - maintenance of healing of erosive esophagitis (1.4) the safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. (8.4) omeprazole and sodium bicarbonate is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. [see clinical studies (14.1)] gastric ulcer omeprazole and sodium bicarbonate is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. [see clinical studies (14.2)] symptomatic gerd omeprazole and sodium bicarbonate is indicated for the treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. [see clinical studies (14.3)

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals llc - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg - lansoprazole delayed-release capsules are indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14)]. triple therapy: lansoprazole delayed-release capsules/amoxicillin/clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release capsules/amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duode

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals,llc - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 300 mg - gabapentin capsules, usp are indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin capsules, usp are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy category c: there are no adequate and well-controlled studies in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. when pregnant mice received oral doses of gabapentin (500, 1000, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effec

Australia - English - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd - 17184 - catheter, angioplasty, balloon dilatation - the device is a monorail brand rapid exchange catheter with a semi-compliant balloon fixed at the distal tip. the balloon catheter has a coaxial shaft design. the outer lumen is used for inflation of the balloon, and the wire lumen permits the use of guidewires 0.014in or 0.018in to facilitate advancement of the catheter to and through the stenosis to be dilated. indicated for percutaneous transluminal angioplasty in the peripheral vasculature, including iliac, femoral, ilio-femoral, popliteal, renal, and carotid arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. also indicated for post-dilatation of balloon expandable and self-expanding stents in the peripheral vasculature.

United States - English - NLM (National Library of Medicine)

sterling knight pharmaceuticals, llc - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 7.5 mg - meloxicam tablets, usp is indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies ( 14.1) ]. meloxicam tablets, usp is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age and older [ see clinical studies ( 14.2) ]. meloxicam is contraindicated in patients with known hypersensitivity (e.g., anaphylactoid reactions and serious skin reactions) to meloxicam. meloxicam should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [ see warnings

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

sterling surfactants ltd, tanzania - triclosan - liquid - 0.1

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

sterling surfactants ltd, tanzania - triclosan - liquid - 0.2

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

sterling surfactants ltd, tanzania - triclosan - liquid - 1

United States - English - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - this product is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, xerosis, ichthyosis, skin cracks and fissures, dermatitis, eczema, psoriasis, keratoses and calluses. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product